Supplementary figure: Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use

These are peer-reviewed supplementary materials for the article 'Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use' published in the Journal of Comparative Effectiveness Research.Supplementary Figure 1: Time to biologic initiation during the 2-year follow-up period among patients with 2 years of follow-upSupplementary Table 1: Patient demographic characteristics and prescriber specialtySupplementary Table 2: Baseline comorbiditiesSupplementary Table 3: Baseline medication useSupplementary Table 4: Baseline healthcare utilization, and costsSupplementary Table 5: Number of index medication fills before biologic initiation during the 1-year follow-up periodSupplementary Table 6: First biologic medication used during the 1-year follow-up period among apremilast patients who initiated biologicSupplementary Table 7: First biologic medication used during the 1-year follow-up period among methotrexate patients who initiated biologicSupplementary Table 8: Biologic initiation adjusted resultsAim: To compare rates of biologic initiation after commencing treatment with apremilast (APR) versus methotrexate (MTX) in systemic-naive patients with psoriasis (PsO). Methods: This was a retrospective cohort study of systemic-naive patients with PsO who initiated treatment with APR or MTX between 1 January 2015 and 31 March 2018. Outcomes: Adjusted rates of biologic initiation during follow-up were compared by logistic and Cox regressions. Results: APR initiators had 58% lower likelihood of biologic initiation (odds ratio: 0.42; 95% CI: 0.37–0.48; p < 0.001), lower adjusted biologic initiation rate (14.4% [95% CI: 13.2–15.7%] vs 28.6% [95% CI: 26.8–30.5%]), lower risk of biologic initiation (hazard ratio: 0.45; 95% CI: 0.40–0.51; p < 0.001) compared with MTX initiators. Conclusion: Systemic-naive patients with PsO have a lower rate of biologic initiation over 1 year following APR initiation.

本数据集为发表于《比较疗效研究杂志》的论文《系统性初治银屑病患者首次使用阿普米单抗与甲氨蝶呤的生物制剂启动率》的同行评审补充材料。补充图1：2年随访期间，具有2年随访数据的患者生物制剂启动时间。补充表1：患者人口统计学特征及处方者专业领域。补充表2：基线合并症。补充表3：基线用药情况。补充表4：基线医疗利用及费用。补充表5：1年随访期间生物制剂启动前索引药物处方次数。补充表6：阿普米单抗启动生物制剂患者1年随访期间首次使用的生物制剂。补充表7：甲氨蝶呤启动生物制剂患者1年随访期间首次使用的生物制剂。补充表8：生物制剂启动调整结果。研究目的：比较系统性初治银屑病患者在开始使用阿普米单抗（APR）与甲氨蝶呤（MTX）治疗后的生物制剂启动率。研究方法：本研究为2015年1月1日至2018年3月31日期间启动APR或MTX治疗的系统性初治银屑病患者的回顾性队列研究。研究结果：与MTX启动患者相比，APR启动患者生物制剂启动的可能性降低58%（优势比：0.42；95%置信区间：0.37–0.48；p < 0.001），调整后的生物制剂启动率较低（14.4% [95%置信区间：13.2–15.7%] vs 28.6% [95%置信区间：26.8–30.5%]），生物制剂启动风险较低（风险比：0.45；95%置信区间：0.40–0.51；p < 0.001）。研究结论：系统性初治银屑病患者在阿普米单抗启动后1年内生物制剂启动率较低。